# Seminar 09: Mental Health in Primary Care ## Year 3: Family Medicine Clerkship --- ## Learning Objectives By the end of this seminar, students will be able to: 1. Screen for and diagnose depression in primary care 2. Manage anxiety disorders 3. Assess suicide risk 4. Initiate and monitor psychotropic medications 5. Apply brief behavioral interventions 6. Recognize when to refer to specialty mental health --- ## Seminar Outline ### I. Depression Screening and Diagnosis Depression represents one of the most common conditions encountered in primary care, affecting approximately eight percent of adults in any two-week period, yet it remains underdiagnosed and undertreated. The US Preventive Services Task Force recommends universal depression screening for all adults (Grade B recommendation), with particular attention to populations at elevated risk including postpartum women, patients with chronic medical conditions, and those with prior depressive episodes. Adolescent screening should begin at age twelve. Screening for perinatal depression is recommended during pregnancy and the postpartum period. Effective screening requires systematic integration into clinical workflows using validated instruments, as reliance on spontaneous patient disclosure misses many cases. The Patient Health Questionnaire-9 (PHQ-9) provides a validated, efficient screening and monitoring tool that assesses the nine DSM-5 criteria for major depressive disorder. Each item is scored from zero (not at all) to three (nearly every day) based on symptom frequency over the preceding two weeks. Total scores range from zero to 27 with established severity cutpoints: minimal depression (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27). A score of ten or higher demonstrates good sensitivity and specificity for major depressive disorder and warrants clinical evaluation. The two-item PHQ-2 screens for depressed mood and anhedonia and can serve as an initial screen, with positive responses prompting completion of the full PHQ-9. Question nine specifically addresses thoughts of death or self-harm and requires immediate follow-up whenever endorsed at any level. Major depressive disorder diagnosis requires meeting DSM-5 criteria confirmed through clinical interview following positive screening. The cardinal symptoms are depressed mood and anhedonia (loss of interest or pleasure); at least one must be present. Additional symptoms captured by the mnemonic SIG E CAPS include Sleep disturbance (insomnia or hypersomnia), Interest loss (anhedonia), Guilt or worthlessness, Energy loss or fatigue, Concentration difficulties, Appetite or weight changes, Psychomotor agitation or retardation, and Suicidal ideation. A major depressive episode requires five or more symptoms present during the same two-week period representing change from previous functioning, causing clinically significant distress or functional impairment, and not better explained by substance effects, medical conditions, or other psychiatric disorders. Differential diagnosis considers medical conditions and other psychiatric disorders presenting with depressive symptoms. Hypothyroidism produces fatigue, cognitive slowing, and weight gain mimicking depression; thyroid function testing is warranted in new presentations. Anemia may cause fatigue and poor concentration. Medication side effects from beta-blockers, corticosteroids, interferon, and others can induce depressive symptoms. Bipolar disorder must be considered before initiating antidepressant treatment, as antidepressant monotherapy may precipitate mania; screen for prior manic or hypomanic episodes including periods of decreased need for sleep, increased energy, racing thoughts, impulsivity, or grandiosity. Adjustment disorder involves depressive symptoms temporally related to identifiable stressors but not meeting full major depressive episode criteria. Persistent depressive disorder (dysthymia) involves chronic depressed mood more days than not for at least two years with additional depressive symptoms. Panel A: USPSTF depression screening recommendations by population including adults, adolescents, and perinatal women. Panel B: PHQ-9 instrument with scoring interpretation and clinical action thresholds. Panel C: DSM-5 major depressive episode criteria checklist using SIG E CAPS mnemonic. Panel D: Depression differential diagnosis including medical causes, medications, and psychiatric conditions to exclude. --- ### II. Depression Treatment Treatment selection should involve patients in shared decision-making discussions weighing options based on severity, preferences, prior treatment history, and access to resources. For mild depression (PHQ-9 scores 5-9), active monitoring with supportive counseling, lifestyle interventions including exercise, and watchful waiting may suffice initially, with reassessment in four to eight weeks. Moderate depression (scores 10-14) warrants either psychotherapy or pharmacotherapy as initial treatment based on patient preference. Moderately severe to severe depression (scores 15 and above) benefits from combination treatment with both medication and psychotherapy when accessible, as combination produces superior outcomes to either alone. Presence of suicidal ideation requires immediate safety assessment and may necessitate urgent psychiatric referral. Psychotherapy offers efficacious treatment for depression through multiple evidence-based modalities. Cognitive behavioral therapy (CBT) addresses negative thought patterns (cognitive distortions) and behavioral withdrawal through structured skill-building typically over twelve to sixteen sessions; robust evidence supports its efficacy equivalent to medication for mild to moderate depression. Interpersonal therapy focuses on improving communication patterns and resolving interpersonal difficulties contributing to depression. Problem-solving therapy helps patients systematically address life problems maintaining depressive symptoms. Behavioral activation specifically targets activity reduction and avoidance through graduated re-engagement with pleasurable and meaningful activities; it may be delivered in briefer formats suitable for primary care. Access to skilled therapists varies by location, and teletherapy has expanded options for many patients. Selective serotonin reuptake inhibitors (SSRIs) represent first-line pharmacotherapy for most patients with major depressive disorder. Commonly used agents include sertraline (starting dose 50 mg daily), which has strong cardiac safety data; escitalopram (starting dose 10 mg daily), which is generally well-tolerated; fluoxetine (starting dose 20 mg daily), which has a long half-life reducing discontinuation symptoms; and citalopram (starting dose 20 mg daily), though higher doses carry QTc prolongation risk. Paroxetine is effective but has more anticholinergic side effects and notable discontinuation syndrome requiring gradual tapering. Common SSRI side effects include gastrointestinal symptoms (usually transient), insomnia or somnolence, sexual dysfunction, and initial anxiety activation. Patients should be warned that therapeutic benefits take two to four weeks to emerge, while side effects often occur earlier; this understanding improves adherence through the initial period. Serotonin-norepinephrine reuptake inhibitors (SNRIs) including duloxetine and venlafaxine offer alternatives to SSRIs, with particular utility for patients with comorbid pain syndromes or when SSRIs have been ineffective. Bupropion, a norepinephrine-dopamine reuptake inhibitor, avoids sexual side effects and weight gain common to SSRIs, making it suitable for patients concerned about these effects; it is contraindicated in patients with seizure disorders, eating disorders, or concurrent use of other medications lowering seizure threshold. Mirtazapine provides sedating properties useful for patients with insomnia and appetite-stimulating effects helpful for those with poor appetite; it causes weight gain limiting its use in some patients. Tricyclic antidepressants are effective but limited by side effect burden and overdose lethality, restricting their role to treatment-resistant cases or specific pain syndromes. Panel A: Treatment selection algorithm based on depression severity, patient preference, and access to therapy. Panel B: Evidence-based psychotherapy modalities with mechanisms, session structures, and appropriate populations. Panel C: SSRI comparison table showing agents, starting doses, and distinguishing features. Panel D: Alternative antidepressants (SNRIs, bupropion, mirtazapine) with specific indications and precautions. --- ### III. Depression Follow-Up Monitoring treatment response requires structured follow-up at defined intervals with objective symptom assessment. Initial contact at one to two weeks after starting medication assesses tolerability, addresses side effect concerns that might lead to discontinuation, and provides reassurance during the period before therapeutic effects emerge. Follow-up at four to six weeks assesses early treatment response using PHQ-9 scores compared to baseline. Ongoing reassessment continues monthly until stable improvement, then less frequently. Documentation should include PHQ-9 scores at each visit to track trajectory objectively. Medication adherence should be assessed at each encounter, as non-adherence commonly explains apparent treatment failure. Response categories guide treatment decisions at reassessment. Response is defined as fifty percent or greater improvement in PHQ-9 score and indicates the current treatment is working; continue and target remission. Partial response (25-50% improvement) suggests the treatment has some benefit but may require optimization; consider increasing to maximum tolerated dose or augmenting. Non-response (less than 25% improvement) after adequate trial warrants treatment change. Remission, the ultimate treatment goal, is defined as PHQ-9 score below five and represents recovery from the depressive episode. Achieving remission rather than merely response is important, as residual symptoms predict relapse. Treatment resistance requires systematic evaluation and management strategies. First, verify adherence to the prescribed regimen. Ensure an adequate trial has occurred (four to six weeks at therapeutic dose). Optimize the current medication by increasing to the maximum tolerated dose. If these steps fail, options include switching to a different SSRI or to a different antidepressant class (SNRI, bupropion, mirtazapine), or augmenting the current medication with a second agent such as bupropion, buspirone, lithium, or atypical antipsychotics (aripiprazole, quetiapine). Adding or intensifying psychotherapy should be considered at any stage. Psychiatric referral is appropriate for patients failing two adequate medication trials, those with complex presentations, or when electroconvulsive therapy (ECT) might be indicated for severe or refractory depression. Treatment duration and discontinuation require careful planning to prevent relapse. The relapse rate after a single depressive episode is approximately fifty percent, supporting the recommendation to continue treatment for at least six to twelve months following remission before considering discontinuation. Patients with recurrent depression (three or more episodes), chronic depression, residual symptoms, or severe episodes with suicidal ideation may warrant longer or indefinite maintenance treatment. When discontinuing, gradual tapering over weeks to months minimizes discontinuation syndrome (particularly problematic with paroxetine and venlafaxine) and allows monitoring for early signs of relapse. Patients should be educated about relapse warning signs and instructed to seek prompt care if symptoms return. Panel A: Depression treatment monitoring timeline showing assessment intervals and actions from initiation through maintenance. Panel B: Response categories (response, partial response, non-response, remission) with definitions and corresponding clinical actions. Panel C: Treatment resistance management algorithm showing optimization, switching, augmentation, and referral pathways. Panel D: Treatment duration guidance based on episode history and relapse risk factors with tapering principles. --- ### IV. Anxiety Disorders Generalized anxiety disorder (GAD) involves persistent, excessive worry about multiple life domains occurring more days than not for at least six months and difficult to control. The worry is accompanied by at least three of six associated symptoms: restlessness or feeling on edge, easy fatigability, difficulty concentrating, irritability, muscle tension, and sleep disturbance. The Generalized Anxiety Disorder 7-item scale (GAD-7) provides validated screening and monitoring with scores of five to nine indicating mild anxiety, ten to fourteen moderate, and fifteen or above severe anxiety. Patients with GAD often present with somatic complaints including headaches, gastrointestinal distress, and chronic pain rather than explicitly reporting worry, requiring clinician awareness of these presentations. Medical conditions mimicking anxiety, including hyperthyroidism, arrhythmias, and pheochromocytoma, should be considered when clinical features suggest. Panic disorder features recurrent unexpected panic attacks, which are abrupt surges of intense fear or discomfort peaking within minutes and accompanied by at least four physical or cognitive symptoms. Physical symptoms include palpitations, sweating, trembling, shortness of breath, chest pain, nausea, dizziness, and paresthesias. Cognitive symptoms include derealization, depersonalization, fear of losing control, and fear of dying. Diagnosis requires recurrent unexpected attacks followed by at least one month of persistent concern about additional attacks, worry about attack implications (heart attack, losing control, going crazy), or significant behavioral changes related to attacks. First panic attacks often prompt emergency evaluation for cardiac or other serious conditions; normal workup with characteristic symptom description should prompt consideration of panic disorder. Social anxiety disorder involves marked fear or anxiety about social situations where scrutiny by others may occur. Individuals fear acting in ways that will be negatively evaluated, humiliated, or embarrassed, leading to avoidance of social interactions, public speaking, meeting new people, or performance situations. The anxiety is persistent (typically six months or longer) and causes significant distress or impairment in social, occupational, or other functioning. Social anxiety often begins in adolescence and may be dismissed as shyness, leading to delayed recognition and treatment. Phobias and agoraphobia represent additional anxiety presentations: specific phobias involve marked fear of particular objects or situations (heights, animals, blood-injection-injury, flying); agoraphobia features anxiety about situations where escape might be difficult or help unavailable, often resulting in progressive restriction of activities. Anxiety disorder treatment effectively employs both psychotherapy and pharmacotherapy. Cognitive behavioral therapy demonstrates robust efficacy for all anxiety disorders, with core components including psychoeducation about anxiety, cognitive restructuring addressing catastrophic thinking, and exposure therapy systematically confronting feared situations to extinguish anxiety responses. SSRIs and SNRIs provide first-line pharmacotherapy, with sertraline, escitalopram, and duloxetine carrying FDA approval for GAD; other SSRIs are also effective. Buspirone offers a non-benzodiazepine option for GAD without sedation or dependence risk, though it requires consistent daily dosing for several weeks before efficacy emerges. Benzodiazepines rapidly relieve acute anxiety but carry dependence risk, cognitive effects, and potential for worsening long-term outcomes; they should be reserved for short-term use during acute crisis while awaiting SSRI/SNRI response or for occasional situational anxiety, with clear duration limits established at initiation. Panel A: Generalized anxiety disorder diagnostic criteria and GAD-7 screening tool with scoring interpretation. Panel B: Panic attack symptom cluster and panic disorder diagnostic criteria with typical patient presentation. Panel C: Social anxiety disorder distinguishing features and avoidance patterns affecting function. Panel D: Anxiety treatment comparison showing CBT components, medication options, and benzodiazepine cautions. --- ### V. Suicide Risk Assessment Suicide risk assessment constitutes an essential competency for all clinicians, as primary care providers see most patients who die by suicide in the weeks before their deaths. Warning signs requiring immediate evaluation include direct statements about wanting to die or kill oneself, seeking access to lethal means (firearms, medications), giving away possessions, saying goodbye, social withdrawal, dramatic mood changes, and expressions of hopelessness or feeling trapped. Static risk factors that cannot be modified include prior suicide attempt (the single strongest predictor of future suicide), male sex, older age, white race, and family history of suicide. Dynamic risk factors amenable to intervention include current psychiatric illness (particularly depression and substance use disorders), access to lethal means, recent loss or crisis, hopelessness, social isolation, chronic pain, and recent discharge from psychiatric hospitalization. Structured assessment ensures thorough evaluation and documentation. Ask directly about suicidal thoughts using clear language such as "Are you having thoughts of suicide?" or "Are you thinking about killing yourself?" If ideation is present, explore further to assess severity: frequency and duration of thoughts, specific plan, access to means, intent to act, and timeline. The Columbia Suicide Severity Rating Scale (C-SSRS) provides a validated structured approach progressing from screening questions (wish to be dead, active suicidal ideation) through assessment of ideation with intent, ideation with specific plan, and any preparatory behaviors. Recent and lifetime suicide attempt history should be documented. Protective factors to assess include reasons for living, social support, responsibility for children or dependents, religious or cultural beliefs against suicide, and engagement in treatment. Risk stratification guides disposition and intervention intensity. Low risk involves passive ideation (wishing to be dead) without intent or plan, presence of protective factors, no recent attempt history, and stable social situation; outpatient management with safety planning, close follow-up, and means restriction counseling may suffice. Moderate risk includes active suicidal ideation with some intent but no specific plan, or recent increase in risk factors; consideration of higher level of care, enhanced outreach, and more intensive follow-up is warranted. High risk involves active ideation with intent and specific plan, access to lethal means, recent preparatory behavior, or limited protective factors; emergency psychiatric evaluation and likely hospitalization are indicated. Risk assessment is not a one-time event but requires ongoing reassessment as circumstances change. Safety planning collaboratively develops a written, personalized plan patients can use during suicidal crisis. The six-step structure includes: (1) warning signs recognizing when crisis is building (thoughts, feelings, behaviors); (2) internal coping strategies the patient can use independently (relaxation techniques, distraction, physical activity); (3) social contacts and settings providing distraction (people to be around, places to go); (4) supportive people the patient can contact when coping strategies are insufficient; (5) professionals and crisis resources including the 988 Suicide and Crisis Lifeline; and (6) means restriction strategies to reduce access to lethal methods. Lethal means counseling specifically addresses reducing access to firearms and medications; brief counseling about safe storage saves lives. Safety plans should be documented in the medical record, provided to patients in writing (paper and/or digital), and reviewed at follow-up visits. Panel A: Suicide warning signs and risk factors organized by static (non-modifiable) and dynamic (modifiable) categories. Panel B: Direct assessment approach with specific questions for ideation, plan, means, and intent. Panel C: Risk stratification matrix showing low, moderate, and high risk criteria with corresponding interventions. Panel D: Six-step safety plan template with example content for each component. --- ### VI. Substance Use Disorders Alcohol use disorder screening should occur routinely in primary care given the high prevalence and health impact of unhealthy alcohol use. The AUDIT-C provides a brief three-item screen asking about drinking frequency, typical quantity on drinking days, and frequency of binge drinking (six or more drinks on one occasion); scores of three or higher in women and four or higher in men warrant further evaluation. The single-question screen asks about heavy drinking days (five or more drinks for men, four or more for women in a single day) in the past year; any positive response indicates at-risk drinking. Standard drink definitions (twelve ounces of regular beer, five ounces of wine, 1.5 ounces of distilled spirits) should be explained when assessing quantity. Recommended drinking limits for adults who drink are up to one drink per day for women and up to two per day for men, with certain populations (pregnancy, driving, specific medications) advised to abstain entirely. Alcohol use disorder diagnosis uses DSM-5 criteria assessing eleven symptoms over the preceding twelve months, grouped into impaired control (drinking more or longer than intended, unsuccessful efforts to cut down, time spent obtaining or recovering from alcohol, craving), social impairment (failure to fulfill role obligations, continued use despite social or interpersonal problems, activities given up), risky use (use in physically hazardous situations, continued use despite physical or psychological problems), and pharmacological criteria (tolerance, withdrawal). Two or more criteria indicate alcohol use disorder, classified as mild (2-3 criteria), moderate (4-5 criteria), or severe (six or more criteria). Severity classification informs treatment intensity recommendations. Brief intervention using the SBIRT framework (Screening, Brief Intervention, and Referral to Treatment) provides effective primary care-based treatment for at-risk drinking and mild alcohol use disorder. Following positive screening, brief intervention provides personalized feedback on drinking levels compared to recommended limits and population norms, clear advice to reduce or abstain, and assessment of readiness to change. Motivational interviewing techniques explore ambivalence about change non-judgmentally and elicit patient-generated reasons for reducing consumption. Brief interventions can be delivered in five to fifteen minutes and demonstrate efficacy in reducing drinking among hazardous drinkers. For moderate to severe alcohol use disorder, referral to specialty addiction treatment provides access to more intensive behavioral therapies and medication management; warm handoffs improve treatment engagement. Pharmacotherapy for alcohol use disorder reduces heavy drinking and supports abstinence when combined with behavioral interventions. Naltrexone, available as daily oral (50 mg) or monthly extended-release injection (380 mg) formulations, reduces craving and heavy drinking days by blocking opioid receptors involved in alcohol's rewarding effects; it is contraindicated in patients currently using opioids due to precipitated withdrawal risk. Acamprosate (666 mg three times daily) modulates glutamate neurotransmission and helps maintain abstinence in patients who have already stopped drinking. Disulfiram creates an aversive reaction to alcohol through acetaldehyde accumulation causing flushing, nausea, and palpitations; it requires excellent motivation and is most effective with observed administration. These medications can be prescribed in primary care without specialty consultation for appropriate patients. Panel A: Alcohol screening tools (AUDIT-C, single question) with scoring thresholds and recommended drinking limits. Panel B: DSM-5 alcohol use disorder criteria organized by impaired control, social impairment, risky use, and pharmacological domains. Panel C: SBIRT brief intervention components with example dialogue using motivational interviewing principles. Panel D: Pharmacotherapy options (naltrexone, acamprosate, disulfiram) with mechanisms, dosing, and patient selection considerations. --- ### VII. Opioid Use Disorder Opioid use disorder has reached epidemic proportions, with over two million Americans affected and over eighty thousand opioid-related overdose deaths annually. The disorder develops through various pathways including prescribed opioids for pain management that evolve to misuse, diverted prescription opioids, and initiation with heroin or illicitly manufactured synthetic opioids (particularly fentanyl). DSM-5 criteria parallel alcohol use disorder, assessing impaired control (larger amounts or longer duration than intended, unsuccessful attempts to cut down, time spent obtaining or using, craving), social impairment, risky use, and pharmacological criteria (tolerance, withdrawal). Physical signs of opioid use include pinpoint pupils, drowsiness, and injection marks. Overdose presents with respiratory depression, unresponsiveness, and cyanosis; naloxone administration reverses opioid effects and saves lives. Office-based opioid treatment with buprenorphine represents an accessible, effective primary care-based approach to opioid use disorder. Buprenorphine, a partial opioid agonist, reduces cravings and withdrawal symptoms while having a ceiling effect that limits respiratory depression risk compared to full agonists. Following regulatory changes removing the X-waiver requirement, any DEA-registered clinician with a standard Schedule III prescribing authority can prescribe buprenorphine for opioid use disorder without additional certification. Induction begins after the patient enters mild to moderate withdrawal (typically 12-24 hours after last opioid use) to avoid precipitating withdrawal from displacing full agonists; home induction protocols enable initiation outside office settings when appropriate. Maintenance dosing typically ranges from 8 to 24 mg sublingually daily. Combining buprenorphine with psychosocial support and periodic monitoring enhances outcomes. Extended-release injectable naltrexone (380 mg monthly intramuscular injection) offers an alternative medication approach using opioid antagonism rather than agonist substitution. Complete opioid abstinence for seven to fourteen days before initiation is required to avoid precipitating withdrawal, as naltrexone blocks opioid receptors. This required abstinence period represents a significant barrier, with many patients relapsing before completing detoxification. Naltrexone may particularly suit patients preferring non-agonist treatment, those in the criminal justice system, healthcare professionals requiring documented abstinence, or patients who have not succeeded with buprenorphine or methadone. Methadone, a full opioid agonist, remains highly effective but requires administration through certified opioid treatment programs (OTPs) rather than office-based prescribing. Harm reduction strategies reduce morbidity and mortality regardless of current treatment engagement. Naloxone (Narcan) distribution and education for patients with opioid use disorder and their contacts enables rapid overdose reversal; prescriptions should be offered to all patients with opioid use disorder and considered for those prescribed high-dose opioids for chronic pain. Syringe service programs reduce infectious disease transmission including HIV and hepatitis C. Fentanyl test strips allow users to detect fentanyl contamination in drug supplies. Non-judgmental healthcare engagement maintains connection with patients not yet ready for formal treatment, keeping doors open for future recovery. These strategies save lives while respecting patient autonomy and meeting people where they are in their recovery journey. Panel A: Opioid use disorder epidemiology, progression pathways, and overdose recognition. Panel B: Buprenorphine treatment protocol showing withdrawal assessment, induction timing, and maintenance management. Panel C: Extended-release naltrexone pathway including detoxification requirements, injection administration, and appropriate patient selection. Panel D: Harm reduction strategies including naloxone distribution, syringe services, and fentanyl testing rationale. --- ### VIII. Integrated Behavioral Health The collaborative care model integrates behavioral health treatment into primary care through systematic team-based management. Core components include a behavioral health care manager who provides care coordination, tracks patient outcomes using validated measures, delivers brief interventions, and coordinates communication among team members; a psychiatric consultant who reviews caseload with the care manager, provides recommendations for treatment adjustments, and offers consultation for complex cases without directly seeing most patients; and the primary care provider who remains the prescribing clinician and maintains the treatment relationship. Measurement-based care using PHQ-9 and GAD-7 at each contact enables systematic treatment adjustment based on objective outcomes. Robust evidence from randomized trials demonstrates improved depression and anxiety outcomes compared to usual primary care, with particular benefit for patients who would not otherwise access specialty mental health treatment. Primary care behavioral health (PCBH) places behavioral health consultants within primary care practices to provide brief, same-day interventions. Unlike traditional mental health care with extended sessions and ongoing therapy relationships, PCBH consultants typically see patients for brief visits (fifteen to thirty minutes) focused on specific concerns, provide immediate warm handoff access, and serve the entire practice population rather than maintaining traditional caseloads. Conditions addressed include depression, anxiety, adjustment to chronic illness, health behavior change (smoking, diet, exercise, medication adherence), and initial assessment for patients who may need specialty mental health referral. The model emphasizes population health principles, with consultants contributing to practice-wide screening and outreach efforts. Telehealth has dramatically expanded access to mental health services, particularly for patients in underserved areas, those with transportation barriers, or individuals who prefer the convenience and privacy of home-based care. Video-based psychotherapy and medication management demonstrate equivalent effectiveness to in-person care for most conditions. Asynchronous modalities including messaging-based therapy and app-based interventions extend reach further. Integration with primary care may involve telehealth psychiatric consultations supporting primary care prescribing, remote collaborative care management, or direct-to-patient specialty mental health services coordinated with primary care teams. Technology enables population-based outreach to patients overdue for follow-up. Addressing mental health disparities requires attention to cultural factors, access barriers, and workforce limitations. Stigma surrounding mental illness varies across cultures and communities; normalizing mental health as part of overall health and using culturally appropriate language reduces this barrier. Language access through professional interpreters ensures accurate communication for patients with limited English proficiency; family members should not serve as interpreters for mental health discussions. Socioeconomic barriers including insurance limitations, transportation, childcare, and work schedule inflexibility limit access to care; telehealth, flexible scheduling, and community-based services help address these barriers. Workforce shortages particularly affect rural and underserved areas, making primary care-based treatment through collaborative care and PCBH models essential for expanding access. Panel A: Collaborative care model diagram showing care manager, psychiatric consultant, and primary care provider roles with communication flows. Panel B: Primary care behavioral health consultant scope of practice with typical visit structure and conditions addressed. Panel C: Telehealth modalities for mental health including synchronous video visits, asynchronous messaging, and technology-enabled population management. Panel D: Mental health disparities framework addressing stigma, language access, socioeconomic barriers, and workforce solutions. --- ### IX. Special Populations Perinatal mental health encompasses depression and anxiety occurring during pregnancy and the postpartum period, affecting approximately one in seven women. Screening is recommended at least once during pregnancy and once during the postpartum period using instruments such as the Edinburgh Postnatal Depression Scale (EPDS) or PHQ-9. Risk factors include personal or family psychiatric history, inadequate social support, unintended pregnancy, pregnancy complications, and history of perinatal loss. Untreated perinatal depression affects maternal health, mother-infant bonding, and child development outcomes. Treatment decisions must consider medication effects on the fetus during pregnancy and on breastfeeding infants; SSRIs (particularly sertraline with minimal breast milk transfer) are generally considered acceptable when indicated, as the risks of untreated depression often exceed medication risks. Psychotherapy provides effective non-pharmacological treatment. Postpartum psychosis is rare (one to two per thousand births) but constitutes a psychiatric emergency requiring immediate hospitalization given risk of harm to self or infant. Adolescent depression requires age-appropriate assessment and treatment approaches. Depression rates have increased substantially among adolescents in recent years. The PHQ-A (modified for adolescents) provides appropriate screening. Presentations may differ from adult depression, with irritability and anger often more prominent than sad mood. Interviews should include time alone with the adolescent separate from parents to enable confidential disclosure about sensitive topics; limits of confidentiality (safety concerns requiring parental involvement) should be explained clearly. Evidence-based psychotherapy including CBT is generally preferred as initial treatment for mild to moderate adolescent depression. When medication is indicated, fluoxetine has FDA approval for ages eight and older and escitalopram for ages twelve and older; other SSRIs are used off-label. The FDA black box warning regarding increased suicidal ideation in youth requires close monitoring, particularly during the first few months of treatment and with dose changes. Older adult mental health presentations may differ from younger adults, requiring adapted assessment and treatment. Depression may present with more somatic complaints, cognitive symptoms (sometimes termed pseudodementia when cognitive impairment predominates), irritability, or social withdrawal rather than classic depressed mood. Anxiety commonly co-occurs with depression and medical conditions. Medication selection requires attention to altered pharmacokinetics (reduced hepatic metabolism, decreased renal clearance), polypharmacy interactions, and increased sensitivity to side effects; starting doses should be lower and titration slower ("start low, go slow"). Anticholinergic medications should be avoided given delirium and cognitive impairment risks. Fall risk increases with many psychotropic medications including benzodiazepines, sedating antidepressants, and antipsychotics. Cognitive screening using instruments such as the Montreal Cognitive Assessment (MoCA) helps distinguish depression-related cognitive symptoms from neurocognitive disorders. Patients with chronic medical conditions experience elevated rates of depression and anxiety that complicate disease management. Diabetes, cardiovascular disease, chronic pain, cancer, and neurological conditions are all associated with substantially increased depression prevalence compared to general populations. Bidirectional relationships exist: depression worsens disease control through impaired self-management and medication adherence, while disease burden and limitations worsen depression. Screening should be routine for patients with these conditions. Treatment selection may consider dual benefit, such as duloxetine for depression with comorbid chronic pain or diabetic neuropathy. Addressing depression improves both mental health outcomes and, in some cases, medical disease control and overall mortality. Panel A: Perinatal mental health screening timeline, risk factors, and treatment considerations balancing maternal and fetal/infant welfare. Panel B: Adolescent depression presentation differences, confidentiality approach, and treatment considerations including monitoring requirements. Panel C: Geriatric mental health considerations including atypical presentations, medication safety, and cognitive screening. Panel D: Chronic disease and depression bidirectional relationships with integrated treatment approach. --- ### X. Referral and Collaboration Indications for specialty mental health referral include diagnostic uncertainty when presentations are complex or atypical and clarification would guide treatment; treatment resistance when patients have not responded to two or more adequate medication trials; active suicidal ideation with plan and intent requiring higher level of care; severe functional impairment limiting ability to work, care for self, or maintain relationships; suspected bipolar disorder or psychotic features requiring specialized assessment and treatment; patient preference for specialty care; and need for treatments not available in primary care such as electroconvulsive therapy, transcranial magnetic stimulation, or intensive outpatient programs. Effective referral processes enhance the likelihood that patients will engage with specialty care. Discussion with the patient should normalize the referral, explain the rationale, and address concerns or barriers to engagement. Warm handoffs, when available, provide real-time introduction to the behavioral health provider, dramatically improving follow-through compared to providing a phone number to call. Providing specific resources including provider names, phone numbers, and addresses facilitates connection. Follow-up contact verifies whether the patient connected with the referral and addresses any barriers encountered. Continued primary care involvement maintains the treatment relationship even when specialty care is involved; patients should understand they are not being abandoned. Communication between primary care and mental health specialists optimizes collaborative care. Referral communications should clearly state the referral question (what specific help is needed), relevant history, medications tried with responses, current treatment, and whether consultation or transfer of care is requested. Receiving consultation reports and incorporating recommendations into ongoing care maintains continuity. Regular communication for shared patients ensures coordinated treatment planning. Electronic health record sharing and warm handoffs facilitate real-time collaboration. Care coordination for complex patients may involve scheduled team meetings or case conferences. Emergency situations require immediate action to ensure patient safety. Acute suicidal crisis with imminent risk requires not leaving the patient alone, removing access to lethal means if possible, and arranging emergency psychiatric evaluation (emergency department, mobile crisis team, or calling emergency services). The 988 Suicide and Crisis Lifeline provides 24/7 access to crisis counselors and can dispatch local crisis services. Acute psychosis with disorganization, paranoia, or command hallucinations may require emergency psychiatric evaluation and possible involuntary hospitalization if the patient is unable to care for self or poses danger. Manic episodes with impulsive, risky behavior require similar urgent evaluation. Homicidal ideation or plans mandate immediate action including potential warning of identifiable targets and involvement of law enforcement when appropriate. Panel A: Specialty mental health referral indications organized by diagnostic, treatment resistance, safety, and severity categories. Panel B: Effective referral process from patient discussion through warm handoff to follow-up confirmation. Panel C: Primary care-specialty communication template for referrals and ongoing collaboration. Panel D: Emergency mental health situations with immediate actions and crisis resources. --- ## Summary - Depression screening: USPSTF recommends all adults; PHQ-9 score of 10 or higher warrants clinical evaluation - Depression treatment selection: mild may respond to monitoring or psychotherapy alone; moderate to severe benefits from medication plus therapy - SSRIs first-line: sertraline and escitalopram commonly used; allow four to six weeks for adequate trial; continue six to twelve months after remission - Response monitoring: PHQ-9 at each visit; response equals fifty percent improvement; remission equals score below five - Anxiety treatment: SSRIs/SNRIs first-line pharmacotherapy; CBT highly effective; avoid long-term benzodiazepines - Suicide assessment: ask directly about ideation, plan, means, and intent; stratify risk; complete safety planning with all patients endorsing ideation - Alcohol use disorder: AUDIT-C screening; brief intervention effective for hazardous drinking; naltrexone and acamprosate for moderate-severe disorder - Opioid use disorder: buprenorphine can be prescribed by any DEA-registered clinician; naloxone should be offered to all patients with opioid use disorder - Collaborative care model: care manager plus psychiatric consultant improves outcomes in primary care settings - Adolescent depression: fluoxetine preferred; black box warning requires enhanced monitoring; therapy often first-line for mild-moderate --- ## Key Terms | Term | Definition | |------|------------| | PHQ-9 | Patient Health Questionnaire nine-item depression screening and monitoring tool | | GAD-7 | Generalized Anxiety Disorder seven-item screening tool | | Remission | PHQ-9 score below five; goal of depression treatment | | SBIRT | Screening, Brief Intervention, and Referral to Treatment framework for substance use | | Buprenorphine | Partial opioid agonist medication for opioid use disorder treatment | | Collaborative care | Team-based model integrating behavioral health into primary care with care manager and psychiatric consultant | | Safety planning | Structured six-step intervention developing personalized crisis response plan | | Warm handoff | Real-time introduction between primary care and behavioral health provider | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*